Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder

Overactive Bladder

A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study

Neurourol Urodyn.

Blok B, Van Kerrebroeck P, de Wachter S, Ruffion A, Van der Aa F, Jairam R, Perrouin-Verbe MA, Elneil S

doi: 10.1002/nau.23892.

Overactive Bladder

Long-Term Functional Outcomes of S3 Sacral Neuromodulation for the Treatment of Idiopathic Overactive Bladder

Neuromodulation.

Ismail S, Chartier-Kastler E, Perrouin-Verbe MA, Rose-Dite-Modestine J, Denys P, Phé V

doi: 10.1111/ner.12696.

Urinary Incontinence

Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-month Results of the ARTISAN-SNM Study

J Urol.

McCrery R, Lane F, Benson K, Taylor C, Padron O, Blok B, Wachter S, Pezzella A, Gruenenfelder J, Pakzad M, Perrouin-Verbe MA, Le Normand L, Van Kerrebroeck P, Mangel J, Peters K, Kennelly M, Shapiro A, Lee U, Comiter C, Mueller M, Goldman HB

doi: 10.1097/JU.0000000000000458.

Lower Urinary Tract SymptomsOveractive Bladder

Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study

Low Urin Tract Symptoms.

Kato D, Tabuchi H, Uno S

doi: 10.1111/luts.12188.

Overactive Bladder

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

Neurourol Urodyn.

Mueller ER, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Stoelzel M, Yoon SJ, Al-Shukri S, Rechberger T, Gratzke C

doi: 10.1002/nau.23919.

Overactive BladderUrinary Incontinence

Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health-Related Quality of Life in Patients with Overactive Bladder

doi: 10.1016/j.juro.2017.05.068.

Overactive Bladder

Initial clinical experience with selective bladder denervation for refractory overactive bladder

Neurourol Urodyn.

Tu LM, De Wachter S, Robert M, Dmochowski RR, Miller LE, Everaert K

doi: 10.1002/nau.23881.

Overactive Bladder

Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019

J Urol.

Lightner DJ, Gomelsky A, Souter L, Vasavada SP

doi: 10.1097/JU.0000000000000309

Overactive Bladder

Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months

Int Braz J Urol.

Vecchioli-Scaldazza C, Morosetti C

doi: 10.1590/

Related content

A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study

Long-Term Functional Outcomes of S3 Sacral Neuromodulation for the Treatment of Idiopathic Overactive Bladder

Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-month Results of the ARTISAN-SNM Study

Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health-Related Quality of Life in Patients with Overactive Bladder

Initial clinical experience with selective bladder denervation for refractory overactive bladder

Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019

Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months